More than 20 million people in the U.S. suffer neuropathic pain. At least 25% of those cases are classified as unexplained and considered cryptogenic sensory polyneuropathy (CSPN). There is no information to guide a physician’s drug choices to treat CSPN, but a researcher recently led a first-of-its-kind prospective comparative effectiveness study.
Click here for original story, Most effective drugs for common type of neuropathic pain
Source: ScienceDaily